Drug
Isis 678354
Isis 678354: highest development phase Phase 2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ISIS 678354 NCT03385239 | Phase 2 | Hypertriglyceridemia |
Latest
No recent events.
Follow Isis 678354 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.